… a subset of advanced nonsmall cell lung cancer (aNSCLC) patients (pts) … , we studied the
efficacy and safety of pembrolizumab for … Patient records were reviewed from initial lung cancer …

… of lung cancer, comprising 18.4% of all cancer-… lung cancer are small cell lung cancer (SCLC),
which accounts for approximately 15% of all lung cancers, and non–small cell lung cancer …

… Our purpose was to evaluate safety and efficacy of IO in a cohort of patients with a considerably
older age than that included in most trials. Although the group of the eldest patients was …

… Lung cancer is the leading cause of cancer related deaths worldwide, and non-small cell
lung cancer (NSCLC) accounts for about 85% of overall reported cases.A clinically significant …

… Purpose: The aim of this study was to evaluate the efficacy and toxicity of gemcitabine at
higher doses than had been used previously in patients with non-smallcell lung cancer (NSCLC)…

… developing lung cancer is high in patients with interstitial lung … the treatment of non-small
cell lung cancer (NSCLC) in clinical … We evaluated the efficacy and lung toxicity of nivolumab in …

… Nivolumab has been shown to be effective and safe in previously treated patients with
advanced non-small cell lung cancer (NSCLC). However, little is known regarding its performance …

… advanced non-small cell lung cancer. Here, we report safety and efficacy data from a
large, global, open-label, phase IV trial of erlotinib (Tarceva Lung Cancer Survival Treatment). …

… lung cancer based on the results from phase III clinical trials. We evaluated the real-world
efficacy and safety of … could aid in the efficient immunotherapeutic management of lung cancer. …

… the efficacy and safety of anlotinib treatment in advanced lung cancer in the real world. …
Antiangiogenic drugs show some efficacy in the treatment of advanced lung cancer. Citation6 …